Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03827954 · ClinicalTrials.gov registry record · NA
HeartMapp: Assessment and Treatment for Heart Failure
A NA study, sponsored by Posit Science Corporation.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT03827954 is a NA study that has completed, run by Posit Science Corporation. The registered enrollment target is 28 participants.
The verdict
NCT03827954, a NA study, has completed, sponsored by Posit Science Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
In the current application, the investigators propose to elaborate upon, reconstruct and advance to pivotal trial readiness a recently validated mobile application (HeartMapp), designed for the ecological momentary assessment and treatment of individuals with Heart Failure (HF). Presently, HeartMapp includes physiological modules (PM) that support self-monitoring and exercises that promote heart health, and cognitive modules (CM) that track and enhance cognitive functions. During the first three-months, the investigators will finalize the cognitive training modules within HeartMapp and release through the quality management system. At the completion of software development, the investigators propose to test the relevant usage and progression variables of the algorithm that will be used to direct engagement with the app. The investigators will conduct a single arm, open label, pilot clinical trial to examine feasibility and initial efficacy of the HeartMapp+CT (HeartMapp and computerized plasticity-based adaptive cognitive training). The term "CT" refers to computerized training. The study will enroll 32 adults aged 40 and older with a diagnosis of HF and over sample by 25% to reduce attrition for a total of 24 participants enrolled at the end. Participants will complete follow-up assessments at 3- and 6-months after enrollment.
Interventions
- OTHER HeartMapp+CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-06-05 |
| Est. Completion | 2021-05-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03827954
The ClinicalTrials.gov registry entry for NCT03827954 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Posit Science Corporation, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HeartMapp+CT is the first listed.
NCT03827954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03827954 about?
NCT03827954 is a clinical study titled "HeartMapp: Assessment and Treatment for Heart Failure". In the current application, the investigators propose to elaborate upon, reconstruct and advance to pivotal trial readiness a recently validated mobile application (HeartMapp), designed for the ecological momentary assessment and treatment of individuals with Heart Failure (HF). Presently, HeartMapp...
What is the current status of trial NCT03827954?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2019-06-05. Estimated completion is 2021-05-24.
What interventions are being tested in trial NCT03827954?
The interventions under investigation include: HeartMapp+CT (OTHER).
Who is sponsoring clinical trial NCT03827954?
This trial is sponsored by Posit Science Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.